Allarity Therapeutics Inc. has announced that IP Australia has formally accepted the company's patent application for its proprietary DRP® companion diagnostic specific to stenoparib. This acceptance is a significant step in Allarity's strategy to secure international intellectual property protection for its DRP® technology. The patent will be officially advertised in the Australian Official Journal of Patents on June 26, 2025, followed by a three-month opposition period. If unopposed, the patent is expected to be granted shortly thereafter. Allarity has already secured a European patent for the Stenoparib DRP® and holds multiple patents in the United States, with applications pending in several other countries.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.